As insurers struggle with GLP-1 drug costs, some seek to wean patients off

Raluca Maniță

KFF Health News Sep 4 2025 After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April. Her request for coverage had been denied, the letter said, because she'd had a body mass index of less than 35 when she started Zepbound. The 25-year-old who lives in New York had been taking Zepbound without incident for months, so she was confused: Why was her BMI, which had been around 32 when she started,

As insurers struggle with GLP-1 drug costs, some seek to wean patients off https://www.news-medical.net - 04.09.2025 13:38

din zilele anterioare

As insurers struggle with GLP-1 drug costs, some seek to wean patients off https://www.news-medical.net - 04.09.2025 13:38